studies

1060A AASLD ABSTRACTS HEPATOLOGY, October, 2015
Disclosures:
Ching-Lung Lai - Advisory Committees or Review Panels: Bristol-Myers Squibb,
Gilead Sciences Inc; Consulting: Bristol-Myers Squibb, Gilead Sciences, Inc;
Speaking and Teaching: Bristol-Myers Squibb, Gilead Sciences, Inc
Man-Fung Yuen - Advisory Committees or Review Panels: GlaxoSmithKline,
Bristol-Myers Squibb, Pfizer, GlaxoSmithKline, Bristol-Myers Squibb, Pfizer,
GlaxoSmithKline, Bristol-Myers Squibb, Pfizer, GlaxoSmithKline, Bristol-Myers
Squibb, Pfizer; Grant/Research Support: Roche, Bristol-Myers Squibb,
GlaxoSmithKline, Gilead Science, Roche, Bristol-Myers Squibb, GlaxoSmith-
Kline, Gilead Science, Roche, Bristol-Myers Squibb, GlaxoSmithKline, Gilead
Science, Roche, Bristol-Myers Squibb, GlaxoSmithKline, Gilead Science
The following authors have nothing to disclose: James Fung, Tiffany C. Wong,
Cindy K. Cheung, Kenneth S. Chok, Wing-chiu Dai, Tan To Cheung, William
Sharr, Albert Chan, Sui-Ling Sin, See-Ching Chan, Chung-Mau Lo
Massimo Colombo - Advisory Committees or Review Panels: BRISTOL-MEY-
ERS-SQUIBB, SCHERING-PLOUGH, ROCHE, GILEAD, BRISTOL-MEYERS-SQUIBB,
SCHERING-PLOUGH, ROCHE, GILEAD, Janssen Cilag, Achillion; Grant/
Research Support: BRISTOL-MEYERS-SQUIBB, ROCHE, GILEAD, BRISTOL-MEY-
ERS-SQUIBB, ROCHE, GILEAD; Speaking and Teaching: Glaxo Smith-Kline,
BRISTOL-MEYERS-SQUIBB, SCHERING-PLOUGH, ROCHE, NOVARTIS, GILEAD,
VERTEX, Glaxo Smith-Kline, BRISTOL-MEYERS-SQUIBB, SCHERING-PLOUGH,
ROCHE, NOVARTIS, GILEAD, VERTEX, Sanofi
Alessio Aghemo - Advisory Committees or Review Panels: Gilead Sciences, MSD,
AbbVie, Janssen; Speaking and Teaching: Jannsen, MSD, Abbvie, BMS, Gilead
Sciences
The following authors have nothing to disclose: Stella De Nicola, Maria F.
Donato, Caterina Premoli, Giovanna Lunghi, Patrizia Bono, Matteo A. Manini,
Federica Malinverno, Sara Monico, Paolo Reggiani
1747
Prevalence and Clinical Impact of Hepatitis E Virus in
Immunosuppressed Patient after Liver Transplantation
Stella De Nicola 1 , Maria F. Donato 1 , Caterina Premoli 1 , Giovanna
Lunghi 2 , Patrizia Bono 2 , Matteo A. Manini 1 , Pietro Lampertico 1 ,
Federica Malinverno 1 , Sara Monico 1 , Paolo Reggiani 3 , Massimo
Colombo 1 , Alessio Aghemo 1 ; 1 Division of Gastroenterology and
Hepatology, Fondazione IRCCS Ca’ Granda Ospedale Maggiore
Policlinico, University of Milan, Milan, Italy; 2 Department of Clinical
Chemistry and Microbiology, Bacteriology and Virology Units,
Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico,
Milan, Italy; 3 Division of Surgery and Liver Transplant, Fondazione
IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
Backgruond: HEV infection is a rising health problem, as it is
the cause of acute and chronic hepatitis especially in immunosuppressed
patients. The prevalence of HEV infection in
Italy and its clinical impact on liver transplanted (LT) patients
is unknown. Aim: To investigate the seroprevalence of IgG-IgM
anti-HEV in LT patients and to compare it with patients with
chronic HCV or HBV infection, or healthy Volunteers. Moreover
we evaluated the impact of HEV in transplanted patients
on overall survival, rejection rates, fibrosis progression and
incidence of extra hepatic manifestastions. Methods: Serology
for HEV IgG and IgM was done with Wantai test (ELISA), HEV
RNA (in-house RT-PCR) was tested in all LT patients in at least
two timepoints during the first year following liver transplantation.
Results: 79 patients who underwent liver transplantation
at our center between 2010 and 2014 were enrolled.
The median age at transplantation was 55 years, 11 (14%)
patients were of foreign origins and HCV was the main etiology
57%. 26 transplanted patients (33%) tested positive for
IgG anti HEV, 3 patients, who were IgG anti-HEV negative
at LT developed IgG during the period of observation. None
of 79 patients were positive for HEV RNA. The seroprevalence
in HCV patients 19% (19/100) (p=0.03), HBV patients
12% (12/100) (p=0.0009) and healthy controls 5% (5/199)
(p=0.0001) were significantly lower than in LT patients. The
prevalence was not influenced by fibrosis stage in HBV or
HCV patients. Overall none of the 79 patients had chronic
HEV infection. In terms of clinical endpoints in the LT patients,
no difference was seen in terms of survival after transplantation,
onset of diabetes, onset of kidney disease, onset of
neurological syndromes or fibrosis progression in IgG positive
versus IgG negative patients. Conclusion: Anti-HEV IgG are
common in the Italian general population and even more so in
LT patients or patients with chronic HCV or HBV infection. However,
in our cohort we do not report a major impact in terms of
clinical endpoints in LT patients probably as a consequence of
the 0% rate of chronic HEV infection.
Disclosures:
Pietro Lampertico - Advisory Committees or Review Panels: Bayer, Bayer; Speaking
and Teaching: Bristol-Myers Squibb, Roche, GlaxoSmithKline, Novartis, Gilead,
Bristol-Myers Squibb, Roche, GlaxoSmithKline, Novartis, Gilead
1748
Long-term outcomes after hepatic resection for hepatocellular
carcinoma in patients with sustained virological
responses to interferon therapy for chronic hepatitis C
Shogo Tanaka 1 , Shigekazu Takemura 1 , Akihiro Tamori 2 , Masahiko
Kinoshita 1 , Norifumi Kawada 2 , Shoji Kubo 1 ; 1 Department of
Hepato-Biliary-Pancreatic Surgery, Osaka City University Graduate
School of Medicine, Osaka, Japan; 2 Department of Hepatology,
Osaka City University Graduate School of Medicine, Osaka,
Japan
Background: The long-term outcome after hepatic resection for
hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC)
in patients who had previously achieved sustained virological
responses (SVR) to interferon (IFN) therapy and who achieved
SVR to adjuvant IFN therapy has been inclusive. Method:
The clinical records of 277 patients who underwent hepatic
resection for HCV-related early stage HCC between 1993
and 2012 were retrospectively reviewed. Thirty-seven of the
277 patients had achieved SVR at the detection of HCC (pre-
SVR group). Twenty-three patients achieved SVR after hepatic
resection (post-SVR group). The control group included the
remaining 217 patients who had received IFN therapy but had
not achieved SVR or who had not received IFN therapy. We
investigated the effect of SVR on the postoperative recurrence
and survival. Results: Twenty-two patients (59%) in the pre-SVR
group, 23 (65%) in the post-SVR group, and 164 (59%) in the
control group had postoperative recurrence during the follow-up
periods, respectively (p=0.09). The disease-free survival rate
was significantly better in the pre-SVR group (5/10/15 years:
49%/29%/29%) and the post-SVR group (61%/36%/27%)
than the control group (23%/7%/7%, p=0.000054). The
overall survival rate at 10/15 years after hepatic resection
was 68%/68% in the pre-SVR group, 78%/78% in the post-
SVR group, and 13%/11% in the control group, respectively
(p